Chapter 3 · Part 5: Hair Loss, Acne, and Libido: Why DHT Affects Every Tissue Differently#

If DHT were simply “bad,” then every man with high DHT would be bald, covered in acne, and dealing with an enlarged prostate. He’d also have exceptional sexual function, solid neurological protection, and robust muscle maintenance—because DHT does all of those things too.

The contradiction isn’t a paradox. It’s a design feature. DHT doesn’t have a single effect on the body. It has tissue-specific effects that vary dramatically depending on which organ you’re looking at, which type of 5-alpha-reductase is active there, how dense the local androgen receptors are, and what cofactors are present in that tissue’s microenvironment.

Grasping this tissue specificity is essential—because every systemic intervention that targets DHT hits all tissues at once. You can’t pop a pill that lowers DHT in your scalp without also lowering it in your brain, your genitals, and your muscles.

Hair Loss Is Not a DHT Problem#

It’s a follicle sensitivity problem—with DHT as one contributing variable among several.

Androgenetic alopecia is primarily genetic. Twin studies put heredity at roughly eighty percent of the variation in hair loss patterns. The key genetic variable isn’t DHT levels—it’s how sensitive your hair follicle androgen receptors are, determined by polymorphisms in the androgen receptor gene (specifically, the CAG repeat length on the X chromosome).

Two men with identical DHT levels can have completely different hair outcomes because their follicles respond differently to the same signal. The man with shorter CAG repeats has more sensitive receptors and is more vulnerable to follicular miniaturization. The man with longer repeats can carry the same DHT level and keep a full head of hair into his seventies.

Beyond genetics, local scalp conditions matter on their own. Chronic microinflammation around the follicle, fibrosis of the dermal papilla, impaired blood flow to the scalp, and elevated local prostaglandin D2 all drive follicular miniaturization—and none of them are fixed by cutting DHT.

Then there’s the metabolic connection. Insulin resistance lowers SHBG, raises free testosterone, and consequently ramps up DHT conversion. Men with metabolic syndrome have significantly higher rates of androgenetic alopecia than metabolically healthy controls. Improving insulin sensitivity—through diet, exercise, and body composition management—may do more for hair retention than a 5-alpha-reductase inhibitor in these cases.

Skin Problems Are Multi-Factorial#

If DHT were the sole cause of acne, every high-DHT male would have problem skin. They don’t. The gap reveals what dermatology has known for years: sebaceous gland activity is regulated by multiple inputs, not just androgens.

Insulin and IGF-1 directly stimulate sebocyte proliferation and lipogenesis—independent of DHT. High-glycemic diets that spike insulin produce measurable bumps in sebum production and acne severity. Dietary intervention studies have shown that cutting glycemic load improves acne outcomes—without touching androgen levels.

The gut-skin axis adds another layer. Emerging research connects intestinal permeability and microbiome composition to systemic inflammation that shows up in the skin. This pathway runs entirely outside the androgen system.

DHT does stimulate sebaceous glands. It’s a real contributor. But treating it as the only contributor leads to interventions that address maybe thirty percent of the problem while potentially creating new ones.

Sexual Function: Where DHT Is Irreplaceable#

In contrast to its complicated role in hair and skin, DHT’s contribution to sexual function is straightforward and essential.

DHT acts on androgen receptors in penile cavernous tissue with a potency testosterone can’t match. It’s involved in maintaining erectile tissue structure, regulating nitric oxide synthase in the corpus cavernosum, and translating the neurological signals of arousal into physical response.

This is why 5-alpha-reductase inhibitors carry sexual side effects that aren’t trivial. Clinical trial data reported sexual dysfunction at roughly two to four percent—but post-marketing surveillance and real-world studies suggest the actual incidence may be substantially higher. The gap likely reflects underreporting in trials and the longer exposure windows of clinical practice.

Libido and erectile function have different hormonal dependencies. Libido is primarily testosterone-driven—it’s the desire. Erectile function involves DHT-mediated local tissue effects—it’s the capacity. A man can have adequate testosterone and normal desire but impaired erectile response if DHT is systemically suppressed. The two are not interchangeable.

The Tissue Specificity Problem#

Here’s the fundamental challenge with any systemic DHT intervention: your body expresses two types of 5-alpha-reductase (Type I and Type II) in different proportions across different tissues. The scalp has high Type II activity. The prostate has high Type II activity. The brain has both. The liver has primarily Type I. Muscle tissue has lower overall activity.

Finasteride primarily inhibits Type II. Dutasteride inhibits both. Neither can be aimed at a specific tissue. When you take a systemic 5-alpha-reductase inhibitor, you’re cutting DHT conversion everywhere—in the tissues where you want the effect (scalp) and in the tissues where you don’t (brain, genitals, muscles).

This is the pharmacological equivalent of dimming every light in your house because one room is too bright. The room you wanted darker is darker. So is the kitchen, the bedroom, and the hallway. You can’t isolate the effect because the drug has no idea which room you care about.

Topical approaches—applying finasteride or other anti-androgens directly to the scalp—offer partial tissue selectivity and less systemic exposure. They’re a step in the right direction but still produce some systemic absorption. The bottom line holds: truly tissue-selective DHT modulation through pharmaceuticals remains an unsolved problem.

Decode the Symptom Before Treating It#

The practical takeaway from this multi-dimensional analysis is a diagnostic principle: before pinning any symptom on DHT, map the full landscape of contributing factors.

Hair loss? Check androgen receptor genetics, thyroid function, insulin sensitivity, iron and ferritin levels, scalp inflammation markers, and stress load—on top of DHT.

Acne? Evaluate dietary glycemic load, insulin levels, gut health, and your topical skincare routine—before concluding that systemic androgen suppression is the answer.

Sexual dysfunction? Separate libido (testosterone-dependent) from erectile capacity (DHT-dependent). Check both hormones. Check cardiovascular health, which independently affects erectile function through the nitric oxide pathway.

The multi-factorial approach takes longer than the single-cause story. It demands more testing, more thought, and more nuance. But it delivers better outcomes because it treats the actual problem rather than the most visible variable.

DHT is one actor in a large cast. Blaming it for every scene that goes wrong guarantees you’ll miss the real plot.